Peroxiredoxin-3 is overexpressed in prostate cancer and promotes cancer cell survival by protecting cells from oxidative stress

[1]  Y. Mao,et al.  MiR‐383 is Downregulated in Medulloblastoma and Targets Peroxiredoxin 3 (PRDX3) , 2013, Brain pathology.

[2]  T. Friedlander,et al.  Targeting the androgen receptor. , 2012, The Urologic clinics of North America.

[3]  Xin Fu,et al.  MicroRNA‐23b downregulates peroxiredoxin III in human prostate cancer , 2012, FEBS letters.

[4]  M. Wolter,et al.  Downregulation of PRDX1 by promoter hypermethylation is frequent in 1p/19q-deleted oligodendroglial tumours and increases radio- and chemosensitivity of Hs683 glioma cells in vitro , 2012, Oncogene.

[5]  P. Ray,et al.  Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. , 2012, Cellular signalling.

[6]  G. Sauter,et al.  Peroxiredoxins 3 and 4 are overexpressed in prostate cancer tissue and affect the proliferation of prostate cancer cells in vitro. , 2012, Journal of proteome research.

[7]  Y. Funato,et al.  Regulation of intracellular signalling through cysteine oxidation by reactive oxygen species. , 2012, Journal of biochemistry.

[8]  F. Han,et al.  Dioscin induces cancer cell apoptosis through elevated oxidative stress mediated by downregulation of peroxiredoxins. , 2012, Cancer biology & therapy.

[9]  T. Leto,et al.  Peroxiredoxin 6 translocates to the plasma membrane during neutrophil activation and is required for optimal NADPH oxidase activity. , 2012, Biochimica et biophysica acta.

[10]  Kai Wang,et al.  Polymorphisms of peroxiredoxin 1, 2 and 6 are not associated with esophageal cancer , 2012, Journal of Cancer Research and Clinical Oncology.

[11]  C. Larsson,et al.  Proteomic profiling of follicular and papillary thyroid tumors , 2011, European journal of endocrinology.

[12]  Ying Liang,et al.  Identification of PRDX4 and P4HA2 as metastasis-associated proteins in oral cavity squamous cell carcinoma by comparative tissue proteomics of microdissected specimens using iTRAQ technology. , 2011, Journal of proteome research.

[13]  Yu-Ju Chen,et al.  In-depth Identification of Pathways Related to Cisplatin-induced Hepatotoxicity through an Integrative Method Based on an Informatics-assisted Label-free Protein Quantitation and Microarray Gene Expression Approach* , 2011, Molecular & Cellular Proteomics.

[14]  T. Conrads,et al.  Proteomic Analysis of Ovarian Cancer Proximal Fluids: Validation of Elevated Peroxiredoxin 1 in Patient Peripheral Circulation , 2011, PloS one.

[15]  Dong-Seok Lee,et al.  The role of peroxiredoxin V in (-)-epigallocatechin 3-gallate-induced multiple myeloma cell death. , 2011, Oncology research.

[16]  H. Immervoll,et al.  Expression of the progenitor marker NG2/CSPG4 predicts poor survival and resistance to ionising radiation in glioblastoma , 2011, Acta Neuropathologica.

[17]  I. Ellis,et al.  Expression of thioredoxin system and related peroxiredoxin proteins is associated with clinical outcome in radiotherapy treated early stage breast cancer. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[18]  I. Mills,et al.  The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis , 2011, The EMBO journal.

[19]  P. Thongsuksai,et al.  Differential protein expression in primary breast cancer and matched axillary node metastasis. , 2011, Oncology reports.

[20]  T. Uchiumi,et al.  Peroxiredoxin 2 in the nucleus and cytoplasm distinctly regulates androgen receptor activity in prostate cancer cells. , 2011, Free radical biology & medicine.

[21]  Y. Paik,et al.  Proteomic analysis of pancreatic juice for the identification of biomarkers of pancreatic cancer , 2011, Journal of Cancer Research and Clinical Oncology.

[22]  Y. Soini,et al.  Oxidative stress and counteracting mechanisms in hormone receptor positive, triple-negative and basal-like breast carcinomas , 2011, BMC Cancer.

[23]  L. Dai,et al.  Using proteomic approach to identify tumor-associated proteins as biomarkers in human esophageal squamous cell carcinoma. , 2011, Journal of proteome research.

[24]  R. Day,et al.  Proteomic analysis of stage I endometrial cancer tissue: identification of proteins associated with oxidative processes and inflammation. , 2011, Gynecologic oncology.

[25]  Z. Jia,et al.  Differential expression of peroxiredoxins in prostate cancer: Consistent upregulation of PRDX3 and PRDX4 , 2011, The Prostate.

[26]  Fen-rong Chen,et al.  Silencing Prx1 and/or Prx5 sensitizes human esophageal cancer cells to ionizing radiation and increases apoptosis via intracellular ROS accumulation , 2011, Acta Pharmacologica Sinica.

[27]  Renee Beekman,et al.  The Antioxidant Protein Peroxiredoxin 4 Is Epigenetically Down Regulated in Acute Promyelocytic Leukemia , 2011, PloS one.

[28]  Yong-Man Kim,et al.  Peroxiredoxin 6 Overexpression Attenuates Cisplatin-Induced Apoptosis in Human Ovarian Cancer Cells , 2011, Cancer investigation.

[29]  S. Kang,et al.  Peroxiredoxin II Restrains DNA Damage-induced Death in Cancer Cells by Positively Regulating JNK-dependent DNA Repair* , 2010, The Journal of Biological Chemistry.

[30]  R. Eeles,et al.  The rs10993994 Risk Allele for Prostate Cancer Results in Clinically Relevant Changes in Microseminoprotein-Beta Expression in Tissue and Urine , 2010, PloS one.

[31]  C. Lillig,et al.  Both Thioredoxin 2 and Glutaredoxin 2 Contribute to the Reduction of the Mitochondrial 2-Cys Peroxiredoxin Prx3* , 2010, The Journal of Biological Chemistry.

[32]  B. Wilson,et al.  Inter-related in vitro effects of androgens, fatty acids and oxidative stress in prostate cancer: a mechanistic model supporting prevention strategies. , 2010, International journal of oncology.

[33]  Y. Soini,et al.  Oxidative stress-induced antioxidant enzyme expression is an early phenomenon in ovarian carcinogenesis. , 2010, European journal of cancer.

[34]  S. Hirohashi,et al.  Peroxiredoxin 2 as a chemotherapy responsiveness biomarker candidate in osteosarcoma revealed by proteomics , 2010, Proteomics. Clinical applications.

[35]  P. Tan,et al.  Silencing the Peroxiredoxin III gene inhibits cell proliferation in breast cancer. , 2010, International journal of oncology.

[36]  Yan Wang,et al.  Peroxiredoxins, a novel target in cancer radiotherapy. , 2009, Cancer letters.

[37]  Yuehua Wu,et al.  Prx1 Enhances Androgen Receptor Function in Prostate Cancer Cells by Increasing Receptor Affinity to Dihydrotestosterone , 2009, Molecular Cancer Research.

[38]  A. Vercesi,et al.  Mitochondria and reactive oxygen species. , 2009, Free radical biology & medicine.

[39]  B. Ozpolat,et al.  Downregulation of the c‐MYC target gene, peroxiredoxin III, contributes to arsenic trioxide‐induced apoptosis in acute promyelocytic leukemia , 2009, International journal of cancer.

[40]  Peng Huang,et al.  Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? , 2009, Nature Reviews Drug Discovery.

[41]  M. Cha,et al.  Overexpression of peroxiredoxin I and thioredoxin1 in human breast carcinoma , 2009, Journal of experimental & clinical cancer research : CR.

[42]  C. Winterbourn,et al.  Redox potential and peroxide reactivity of human peroxiredoxin 3. , 2009, Biochemistry.

[43]  W. Choe,et al.  Expression of human peroxiredoxin isoforms in response to cervical carcinogenesis. , 2009, Oncology reports.

[44]  Sun Young Park,et al.  Expression of cystathionine β-synthase is downregulated in hepatocellular carcinoma and associated with poor prognosis , 2009 .

[45]  R. Wolosiuk,et al.  Typical 2‐Cys peroxiredoxins – modulation by covalent transformations and noncovalent interactions , 2009, The FEBS journal.

[46]  P. Karplus,et al.  Typical 2‐Cys peroxiredoxins – structures, mechanisms and functions , 2009, The FEBS journal.

[47]  M. Cannell,et al.  Reversible oxidation of mitochondrial peroxiredoxin 3 in mouse heart subjected to ischemia and reperfusion , 2009, FEBS letters.

[48]  G. Kroemer,et al.  The Warburg Effect Suppresses Oxidative Stress Induced Apoptosis in a Yeast Model for Cancer , 2009, PloS one.

[49]  A. Salmon,et al.  Reduction of mitochondrial H2O2 by overexpressing peroxiredoxin 3 improves glucose tolerance in mice , 2008, Aging cell.

[50]  K. Brown,et al.  The thioredoxin reductase inhibitor auranofin triggers apoptosis through a Bax/Bak-dependent process that involves peroxiredoxin 3 oxidation. , 2008, Biochemical pharmacology.

[51]  Mark J. Dunning,et al.  BASH: a tool for managing BeadArray spatial artefacts , 2008, Bioinform..

[52]  F. Bari,et al.  Mitochondrial-mediated suppression of ROS production upon exposure of neurons to lethal stress: mitochondrial targeted preconditioning. , 2008, Advanced drug delivery reviews.

[53]  Erkki Ruoslahti,et al.  Mitochondrial/cell-surface protein p32/gC1qR as a molecular target in tumor cells and tumor stroma. , 2008, Cancer research.

[54]  K. Brown,et al.  Mitochondrial peroxiredoxin 3 is rapidly oxidized in cells treated with isothiocyanates. , 2008, Free radical biology & medicine.

[55]  Peng Huang,et al.  Redox regulation of cell survival. , 2008, Antioxidants & redox signaling.

[56]  I. Mills,et al.  Alterations in β‐catenin expression and localization in prostate cancer , 2008, The Prostate.

[57]  S. Baek,et al.  Up-Regulation of Peroxiredoxin 1 in Lung Cancer and Its Implication as a Prognostic and Therapeutic Target , 2008, Clinical Cancer Research.

[58]  J. Pullar,et al.  Oxidation of mitochondrial peroxiredoxin 3 during the initiation of receptor-mediated apoptosis. , 2008, Free radical biology & medicine.

[59]  B. Knoops,et al.  Silencing of peroxiredoxin 3 and peroxiredoxin 5 reveals the role of mitochondrial peroxiredoxins in the protection of human neuroblastoma SH-SY5Y cells toward MPP+ , 2008, Neuroscience Letters.

[60]  Jian‐feng Lin,et al.  Identification of candidate prostate cancer biomarkers in prostate needle biopsy specimens using proteomic analysis , 2007, International journal of cancer.

[61]  W. Jin,et al.  Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer , 2007, Breast Cancer Research.

[62]  J. Mohler,et al.  Peroxiredoxin 1 interacts with androgen receptor and enhances its transactivation. , 2007, Cancer research.

[63]  P. Pelicci,et al.  Hydrogen peroxide: a metabolic by-product or a common mediator of ageing signals? , 2007, Nature Reviews Molecular Cell Biology.

[64]  M. Kantorow,et al.  Localization and H2O2-specific induction of PRDX3 in the eye lens. , 2007, Molecular vision.

[65]  S. Tavaré,et al.  beadarray: R classes and methods for Illumina bead-based data , 2007, Bioinform..

[66]  D. Neal,et al.  Labeling and identification of LNCaP cell surface proteins: A pilot study , 2007, The Prostate.

[67]  I. Mills,et al.  A role for neurotensin in bicalutamide resistant prostate cancer cells , 2007, The Prostate.

[68]  Wun-Jae Kim,et al.  Enhanced expression of peroxiredoxin I and VI correlates with development, recurrence and progression of human bladder cancer. , 2006, The Journal of urology.

[69]  A. Gotoh,et al.  Mitochondrial DNA determines androgen dependence in prostate cancer cell lines , 2006, Oncogene.

[70]  G. Bartsch,et al.  The androgen receptor pathway is by‐passed in prostate cancer cells generated after prolonged treatment with bicalutamide , 2006, The Prostate.

[71]  I. Fichtner,et al.  Proteomics of xenografted human breast cancer indicates novel targets related to tamoxifen resistance , 2006, Proteomics.

[72]  C. Bevan.  Androgen receptor in prostate cancer: cause or cure? , 2005, Trends in Endocrinology & Metabolism.

[73]  Seung Soo Shin,et al.  Expression of peroxiredoxin and thioredoxin in human lung cancer and paired normal lung. , 2005, Respirology.

[74]  G. Chanfreau,et al.  Multiple RNA surveillance pathways limit aberrant expression of iron uptake mRNAs and prevent iron toxicity in S. cerevisiae. , 2005, Molecular cell.

[75]  Long Yu,et al.  RPK118, a PX domain-containing protein, interacts with peroxiredoxin-3 through pseudo-kinase domains. , 2005, Molecules and cells.

[76]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[77]  Jean YH Yang,et al.  Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.

[78]  P. Hirvikoski,et al.  Peroxiredoxins, a novel protein family in lung cancer , 2004, International journal of cancer.

[79]  B. Knoops,et al.  Cloning of bovine peroxiredoxins-gene expression in bovine tissues and amino acid sequence comparison with rat, mouse and primate peroxiredoxins. , 2003, Comparative biochemistry and physiology. Part B, Biochemistry & molecular biology.

[80]  Sang Won Kang,et al.  Peroxiredoxins in breast carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[81]  Joon-Hyuk Choi,et al.  Overexpression of mitochondrial thioredoxin reductase and peroxiredoxin III in hepatocellular carcinomas. , 2002, Anticancer research.

[82]  Y. Ikeda,et al.  Advances in our understanding of peroxiredoxin, a multifunctional, mammalian redox protein , 2002, Redox report : communications in free radical research.

[83]  Chi V. Dang,et al.  The c-Myc target gene PRDX3 is required for mitochondrial homeostasis and neoplastic transformation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[84]  Y. Soini,et al.  Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma , 2002, The Journal of pathology.

[85]  Carl Nathan,et al.  Nonredundant Antioxidant Defense by Multiple Two-Cysteine Peroxiredoxins in Human Prostate Cancer Cells , 2002, Molecular medicine.

[86]  D. Noh,et al.  Overexpression of peroxiredoxin in human breast cancer. , 2001, Anticancer research.

[87]  Y. Murasato,et al.  Antioxidant Function of the Mitochondrial Protein SP-22 in the Cardiovascular System* , 1999, The Journal of Biological Chemistry.

[88]  E. Mulder,et al.  Mechanism of antiandrogen action: Conformational changes of the receptor , 1994, Molecular and Cellular Endocrinology.

[89]  G. Lenaz.  Mitochondria and reactive oxygen species. Which role in physiology and pathology? , 2012, Advances in experimental medicine and biology.

[90]  J. Pincemail,et al.  [Oxidative stress]. , 2007, Revue medicale de Liege.

[91]  Gordon K. Smyth,et al.  limma: Linear Models for Microarray Data , 2005 .

[92]  Z. A. Wood,et al.  Structure, mechanism and regulation of peroxiredoxins. , 2003, Trends in biochemical sciences.

[93]  A. Szent-Györgyi.  PHYSIOLOGY AND PATHOLOGY , 1968 .